The U.S. Food and Drug Administration (FDA) has declined to review Soligenix Inc.’s application seeking approval of its cancer treatment, the drug developer said on Tuesday, sending its shares down more than 30% in early trading.
https://www.pharmalive.com/wp-content/uploads/2021/02/Becton-Dickinsons-combination-test-for-COVID-19-gets-FDA-authorization-Reuters-2-12-21.jpeg246370Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2023-02-14 11:15:122023-02-14 11:41:01U.S. FDA declines to review Soligenix's cancer drug; shares sink
